IL153398A0 - Stable gabapentin containing more than 20 ppm of chlorine ion - Google Patents

Stable gabapentin containing more than 20 ppm of chlorine ion

Info

Publication number
IL153398A0
IL153398A0 IL15339801A IL15339801A IL153398A0 IL 153398 A0 IL153398 A0 IL 153398A0 IL 15339801 A IL15339801 A IL 15339801A IL 15339801 A IL15339801 A IL 15339801A IL 153398 A0 IL153398 A0 IL 153398A0
Authority
IL
Israel
Prior art keywords
ppm
chlorine ion
stable gabapentin
stable
gabapentin containing
Prior art date
Application number
IL15339801A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22788993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL153398(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL153398A0 publication Critical patent/IL153398A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
IL15339801A 2000-06-16 2001-06-15 Stable gabapentin containing more than 20 ppm of chlorine ion IL153398A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21196700P 2000-06-16 2000-06-16
PCT/US2001/019100 WO2001097612A1 (en) 2000-06-16 2001-06-15 Stable gabapentin containing more than 2o ppm of chlorine ion

Publications (1)

Publication Number Publication Date
IL153398A0 true IL153398A0 (en) 2003-07-06

Family

ID=22788993

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15339801A IL153398A0 (en) 2000-06-16 2001-06-15 Stable gabapentin containing more than 20 ppm of chlorine ion

Country Status (12)

Country Link
US (1) US6531509B2 (de)
EP (1) EP1289364B1 (de)
AT (1) ATE255891T1 (de)
AU (1) AU2001268426A1 (de)
CA (1) CA2410867C (de)
DE (2) DE60101476T2 (de)
DK (1) DK1289364T3 (de)
ES (1) ES2193008T3 (de)
IL (1) IL153398A0 (de)
PT (1) PT1289364E (de)
TR (1) TR200302296T4 (de)
WO (1) WO2001097612A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294364A4 (de) * 2000-06-16 2004-06-16 Teva Pharma Stabiles gabapentin mit einem ph innerhalb eines kontrollierten bereichs
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
CA2510292A1 (en) * 2002-12-20 2004-07-15 Dynogen Pharmaceuticals, Inc. Methods of treating non-painful bladder disorders using .alpha.2.delta. subunit calcium channel modulators
WO2004084879A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
WO2005041925A2 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CN101462975B (zh) * 2008-08-19 2012-07-25 宁波九胜创新医药科技有限公司 一种高纯度加巴喷丁的制备方法
CN116693410B (zh) * 2023-06-08 2024-06-07 浙江竹子制药有限公司 一种粒径可控的加巴喷丁制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2611690A1 (de) 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
US4960931A (en) 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
US4894476A (en) 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
DE3928182A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
MY106864A (en) 1989-08-25 1995-08-30 Warner Lambert Co Improved process for cyclic amino acid anticonvulsant compounds.
US5319135A (en) 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
DE3928184A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
US5132451A (en) 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
CN100337687C (zh) * 1998-05-15 2007-09-19 沃尼尔·朗伯公司 含有γ－氨基丁酸衍生物的固体组合物及其制备方法
DE69918977T2 (de) * 1998-05-15 2005-07-28 Warner-Lambert Co. Llc Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same

Also Published As

Publication number Publication date
TR200302296T4 (tr) 2004-02-23
EP1289364A4 (de) 2003-08-06
US20020061931A1 (en) 2002-05-23
EP1289364B1 (de) 2003-12-10
DE60101476D1 (de) 2004-01-22
CA2410867A1 (en) 2001-12-27
AU2001268426A1 (en) 2002-01-02
DK1289364T3 (da) 2004-04-13
EP1289364A1 (de) 2003-03-12
DE60101476T2 (de) 2004-05-27
DE1289364T1 (de) 2003-09-18
PT1289364E (pt) 2004-04-30
WO2001097612A1 (en) 2001-12-27
ATE255891T1 (de) 2003-12-15
CA2410867C (en) 2003-12-09
ES2193008T1 (es) 2003-11-01
ES2193008T3 (es) 2004-07-01
US6531509B2 (en) 2003-03-11

Similar Documents

Publication Publication Date Title
IL153398A0 (en) Stable gabapentin containing more than 20 ppm of chlorine ion
YU31399A (sh) Inhibitori sintaze azot-monoksida
IL161187A0 (en) Liposome compositions containing metal ions and therapeutic agents
HK1045705A1 (zh) 含水楊酸硅氧烷凝膠
MX355976B (es) Composiciones antitranspirantes de eficacia mejorada que contienen estroncio.
MXPA04004109A (es) Composiciones cosmeticas anhidras que contienen compuestos de amonio cuaternario.
TW200510375A (en) New compounds
AU2015902A (en) Aluminum-zirconium antiperspirant salts with high peak 5 al content
WO1998023249A3 (en) Oral compositions containing fluoride, pyrophosphate, peroxide, and nonionic and/or amphoteric surfactants
MXPA04006542A (es) Composiciones bucales estables que contienen complejos de fosfopeptido de caseina y fluooruro.
TNSN05275A1 (en) Lactate containing pharmaceutical composition and uses thereof
EP0831761A4 (de) Siliziumdioxid-schleifmittel
DE69905170D1 (en) Thiazolopyrimidinderivate
MXPA03009572A (es) Formas de polialilamina con bajo contenido en sal.
IL142876A0 (en) Nano-emulsion of 5-aminolevulinic acid
TNSN04206A1 (en) Novel perindopril salt and pharmaceutical compositions containing same
AU2249297A (en) Low ph germicidal iodine compositions having enhanced stability
YU95302A (sh) Stabilni gabapentin koji ima ph u kontrolisanom rasponu
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi
HK1080077A1 (zh) 非肽的brs-3激動劑
AU9731198A (en) Histogranin peptide and their analgesic use
ES2192136A1 (es) Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
AP1549A (en) Stabilised hypobromous acid solutions.
CY1108791T1 (el) Φυτοενδυναμωτικο μεσον
RS53304A (en) Ultrapure oral fludara formulation with a fast releasing active substance